Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure
By M. Packer, J. McMurray, Akshay S. Desai, J. Gong, M. Lefkowitz, A. Rizkala, J. Rouleau, V. Shi, S. Solomon, K. Swedberg and 42 more. Circulation, 2015
599 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/8cb00e79d66d61743bc53235a063b00a4c86ff38
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- Gerasimos Filippatos
- K. Weeks
- Bianca C. Bernardo
- J. McMullen
- C. Yancy
- M. Drazner
- Véronique L. Roger
Citations in the corpus
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “In 2 studies with ARNI, NT-proBNP levels were reduced (12,14), with the reduction in 1 study being associated with improved clinical outcomes (12).”
- Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “More recently, the dual angiotensin–neprilysin receptor inhibitor has been shown to be more effective than the current standard treatment (the ACE inhibitor enalapril) at preventing the progression of HF (McMurray et al. 2014; Packer et al. 2015).”